Srinath Kotamarti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Srinath Kotamarti has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Thomas J. Polascik
Department of Urology Wake Forest University Winston‐Salem North Carolina USA
6 shared publications - Eric S. Adams
Department of Urologic Surgery Duke University Medical Center Durham North Carolina USA
4 shared publications - Sriram Deivasigamani
Department of Urologic Surgery Duke University Medical Center Durham North Carolina USA
4 shared publications - Denis Seguier
Department of Urologic Surgery Duke University Medical Center Durham North Carolina USA
3 shared publications Ali Aminsharifi
Department of Urologic Surgery Duke University Medical Center Durham North Carolina USA
2 shared publications- Mahdi Mottaghi
Institute for Medical Research Veteran Affairs Medical System Durham North Carolina USA
2 shared publications
Latest Publications
- 8 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1006-1012
Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy
Background: Focal therapy (FT) encompasses ablation of the prostate cancer (PCa) while preserving the surrounding benign tissue, aiming to minimize or spare patients from postoperative complications. Although FT has been proven effective, the multifocal and heterogeneous nature of PCa is a significant concern regarding the risk of disease progression. The Genomic Prostate Score (GPS) has been shown to aid in the risk stratification of patients with localized disease; however, its role in patients undergoing FT remains unclear. We evaluated the association between the GPS performed on pretreatment biopsy cores and the oncological outcomes of patients with localized PCa treated with FT at our institution. Methods: This is an institutional review board‐approved retrospective review of a prospectively maintained database of PCa patients undergoing prostate FT at Duke between 2005 and 2020. The study included men with localized PCa, preoperative diagnostic prostate biopsy tissue availability, and a minimum follow‐up of 1‐year. The primary outcome was to evaluate the association between the GPS assay performed on the preoperative prostate biopsy tissue with cumulative incidence of treatment‐failure (TF) defined as requirement of salvage therapy and/or development of metastasis, and prostate cancer‐specific death and failure‐free survival (FFS). The secondary outcome was to assess whether the GPS assay could predict ≥ Gleason Grade Group (GGG) 2 biopsy recurrence/persistence following ablation. Results: A total of 81 patients met the inclusion criteria. The median follow‐up was 48 months (IQR, 35–98). The median age, preoperative PSA, and PSA density were 74 years (IQR, 68–77), 7.4 ng/ml (IQR, 5.5–10), and 0.19 ng/mL/mL (0.14–0.22), respectively. Of 81 patients, 55 (68%) and 7 (9%) had intermediate and high‐risk disease. The median GPS score was 30 (IQR, 24–40), and 21/81 (26%) had a GPS result > 40. TF and ≥ GGG2 biopsy recurrence were observed in 15/81 (19%) and 10/81 (12%), respectively. GPS was > 40 in 8/15 (53%) and 7/10 (70%) of patients with TF and biopsy recurrence, respectively. On univariable analysis, GPS was significantly associated with TF (HR 1.07, 95% CI, 1.02–1.12, p < 0.01) and biopsy recurrence/persistence (HR 1.09, 95% CI, 1.03–1.15, p = 0.08). Men with GPS of 40–100 were found to be significantly at higher risk of having TF (HR 4.19, 95% CI, 1.26–13.89, p = 0.01) and in‐field biopsy recurrence (HR 14.3, 95% CI, 2.48–82.83, p = 0.003). Conclusion: Among men treated with focal ablation for localized PCa, the GPS assay appears to be a prognostic indicator of FFS and GGG ≥ 2 biopsy recurrence. Further studies with large sample sizes are required to validate these findings.
- 8 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (9) , 1006-1012
Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy
Background: Focal therapy (FT) encompasses ablation of the prostate cancer (PCa) while preserving the surrounding benign tissue, aiming to minimize or spare patients from postoperative complications. Although FT has been proven effective, the multifocal and heterogeneous nature of PCa is a significant concern regarding the risk of disease progression. The Genomic Prostate Score (GPS) has been shown to aid in the risk stratification of patients with localized disease; however, its role in patients undergoing FT remains unclear. We evaluated the association between the GPS performed on pretreatment biopsy cores and the oncological outcomes of patients with localized PCa treated with FT at our institution. Methods: This is an institutional review board‐approved retrospective review of a prospectively maintained database of PCa patients undergoing prostate FT at Duke between 2005 and 2020. The study included men with localized PCa, preoperative diagnostic prostate biopsy tissue availability, and a minimum follow‐up of 1‐year. The primary outcome was to evaluate the association between the GPS assay performed on the preoperative prostate biopsy tissue with cumulative incidence of treatment‐failure (TF) defined as requirement of salvage therapy and/or development of metastasis, and prostate cancer‐specific death and failure‐free survival (FFS). The secondary outcome was to assess whether the GPS assay could predict ≥ Gleason Grade Group (GGG) 2 biopsy recurrence/persistence following ablation. Results: A total of 81 patients met the inclusion criteria. The median follow‐up was 48 months (IQR, 35–98). The median age, preoperative PSA, and PSA density were 74 years (IQR, 68–77), 7.4 ng/ml (IQR, 5.5–10), and 0.19 ng/mL/mL (0.14–0.22), respectively. Of 81 patients, 55 (68%) and 7 (9%) had intermediate and high‐risk disease. The median GPS score was 30 (IQR, 24–40), and 21/81 (26%) had a GPS result > 40. TF and ≥ GGG2 biopsy recurrence were observed in 15/81 (19%) and 10/81 (12%), respectively. GPS was > 40 in 8/15 (53%) and 7/10 (70%) of patients with TF and biopsy recurrence, respectively. On univariable analysis, GPS was significantly associated with TF (HR 1.07, 95% CI, 1.02–1.12, p < 0.01) and biopsy recurrence/persistence (HR 1.09, 95% CI, 1.03–1.15, p = 0.08). Men with GPS of 40–100 were found to be significantly at higher risk of having TF (HR 4.19, 95% CI, 1.26–13.89, p = 0.01) and in‐field biopsy recurrence (HR 14.3, 95% CI, 2.48–82.83, p = 0.003). Conclusion: Among men treated with focal ablation for localized PCa, the GPS assay appears to be a prognostic indicator of FFS and GGG ≥ 2 biopsy recurrence. Further studies with large sample sizes are required to validate these findings.
- 12 August 2024
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 28 (3) , 755-760
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study
Importance and objective Partial gland ablation (PGA) is increasingly popular as a treatment for men with intermediate-risk prostate cancer (IR-PCa) to preserve functional outcomes while controlling their cancer. We aimed to determine the impact of race and clinical characteristics on the risk of upstaging (≥pT2c) and having adverse pathological outcomes including seminal vesicle invasion (SVI), extra prostatic extension (EPE) and lymph node invasion (LNI) at radical prostatectomy (RP) among men with IR disease eligible for PGA with hemi-ablation (HA). Design Retrospective analysis. Setting Multicenter. Participants and measures We studied patients diagnosed with unilateral IR-PCa treated with RP between 1988 and 2020 at 9 different Veterans Affairs hospitals within the SEARCH cohort. We analyzed differences in clinicopathological characteristics and outcome variables (odds of ≥pT2c and SVI, EPE and LNI) by race using multivariable logistic regression after adjusting for covariates. Results Among 3127 patients, 33% were African American (AA) men with unilateral IR-PCa undergoing RP. Compared to non-AA men, AA individuals were younger (61 vs. 65 years, p < 0.001), presented with a higher prostate specific antigen (PSA) category (≥10 ng/ml; 34 vs. 26%, p < 0.001), and had a lower clinical stage (p < 0.001). Among the 2,798 (89.5%) with ≥pT2c stage, AA men exhibited higher ≥ pT2c rates (93 vs. 89%, p < 0.001), primarily due to increased pT2c staging (64 vs. 57%), where upstaging beyond pT2 was lower than non-AA men (29 vs. 32%). On multivariable analysis, AA men were found to have higher odds of ≥pT2c (odds ratio [OR]: 1.39 CI, 1.02–1.88, p = 0.04), lower odds of EPE (OR: 0.73 CI, 0.58–0.91, p < 0.01) and no statistically significant associations with LNI (OR: 0.79 CI, 0.42–1.46, p = 0.45) and SVI (OR: 1 CI, 0.74–1.35, p = 0.99) compared to non-AA men. On multivariable analysis, clinical features associated with higher odds of ≥pT2c were pre-operative PSA ≥ 15 (OR = 2.07, P = 0.01) and higher number of positive cores (HPC) on biopsy (OR = 1.36, P < 0.001). Similarly, PSA ≥ 15, Gleason grade ≥3 and HPC on biopsy were associated with higher odds of SVI, EPE and LNI, respectively. Conclusions In men with IR-PCa undergoing RP, AA men demonstrated an overall higher likelihood of ≥pT2c with lower upstaging beyond pT2, lower likelihood of EPE and no significant difference in likelihood of SVI and LNI compared to non-AA men. These findings support select AA men to be potential candidates for PGA, such as HA. Clinical factors are predictive of higher pathological stage and adverse pathological outcomes at RP and could be considered when selecting candidates for PGA.
- 12 August 2024
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 28 (3) , 755-760
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—a multicenter SEARCH cohort study
Importance and objective Partial gland ablation (PGA) is increasingly popular as a treatment for men with intermediate-risk prostate cancer (IR-PCa) to preserve functional outcomes while controlling their cancer. We aimed to determine the impact of race and clinical characteristics on the risk of upstaging (≥pT2c) and having adverse pathological outcomes including seminal vesicle invasion (SVI), extra prostatic extension (EPE) and lymph node invasion (LNI) at radical prostatectomy (RP) among men with IR disease eligible for PGA with hemi-ablation (HA). Design Retrospective analysis. Setting Multicenter. Participants and measures We studied patients diagnosed with unilateral IR-PCa treated with RP between 1988 and 2020 at 9 different Veterans Affairs hospitals within the SEARCH cohort. We analyzed differences in clinicopathological characteristics and outcome variables (odds of ≥pT2c and SVI, EPE and LNI) by race using multivariable logistic regression after adjusting for covariates. Results Among 3127 patients, 33% were African American (AA) men with unilateral IR-PCa undergoing RP. Compared to non-AA men, AA individuals were younger (61 vs. 65 years, p < 0.001), presented with a higher prostate specific antigen (PSA) category (≥10 ng/ml; 34 vs. 26%, p < 0.001), and had a lower clinical stage (p < 0.001). Among the 2,798 (89.5%) with ≥pT2c stage, AA men exhibited higher ≥ pT2c rates (93 vs. 89%, p < 0.001), primarily due to increased pT2c staging (64 vs. 57%), where upstaging beyond pT2 was lower than non-AA men (29 vs. 32%). On multivariable analysis, AA men were found to have higher odds of ≥pT2c (odds ratio [OR]: 1.39 CI, 1.02–1.88, p = 0.04), lower odds of EPE (OR: 0.73 CI, 0.58–0.91, p < 0.01) and no statistically significant associations with LNI (OR: 0.79 CI, 0.42–1.46, p = 0.45) and SVI (OR: 1 CI, 0.74–1.35, p = 0.99) compared to non-AA men. On multivariable analysis, clinical features associated with higher odds of ≥pT2c were pre-operative PSA ≥ 15 (OR = 2.07, P = 0.01) and higher number of positive cores (HPC) on biopsy (OR = 1.36, P < 0.001). Similarly, PSA ≥ 15, Gleason grade ≥3 and HPC on biopsy were associated with higher odds of SVI, EPE and LNI, respectively. Conclusions In men with IR-PCa undergoing RP, AA men demonstrated an overall higher likelihood of ≥pT2c with lower upstaging beyond pT2, lower likelihood of EPE and no significant difference in likelihood of SVI and LNI compared to non-AA men. These findings support select AA men to be potential candidates for PGA, such as HA. Clinical factors are predictive of higher pathological stage and adverse pathological outcomes at RP and could be considered when selecting candidates for PGA.
- 26 June 2024
- Published by Wiley in The Prostate
- Vol. 84 (13) , 1224-1233
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes
Purpose: To compare the efficacy of a novel fusion template “reduced six‐core systemic template and multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy” (TBx+6c), with mpMRI/TRUS fusion‐targeted biopsy and 12‐core systematic biopsy template (TBx+12c) in the diagnosis of prostate cancer (PCa).Materials and Methods: This is an institutional review board approved single‐center observational study involving adult men undergoing fusion‐targeted biopsies for the diagnosis of PCa. Patients were sorted into cohorts of TBx+6c or TBx+12c based on the systematic biopsy template used. The study's main objective was to determine the cancer detection rate (CDR) for overall PCa and clinically significant PCa (csPCa) and the secondary objectives were to compare complication rates and functional outcome differences between the cohort.Results: A total of 204 patients met study's inclusion criteria. TBx+6c group had 120 patients, while TBx+12c cohort had 84 patients. The groups had similar baseline characteristics and overall CDR in the TBx+6c cohort was 71.7% versus 79.8%, compared to the TBx+12c (p = 0.18) whereas, the csPCa detection rate in the TBx+6c group was 50.8% versus 54.8% in the TBx+12c group (p = 0.5). TBx+6c cohort had lower overall complication rate of 3% versus 13%, (p = 0.01) and ≥ grade 2 complication rates (1 (1%) vs. 3(4%), p = 0.03) compared to the TBx+12c cohort. There were no differences in IIEF‐5 (p = 0.5) or IPSS (p = 0.1) scores at baseline and 2‐weeks and 6‐weeks post‐biopsy.Conclusion: TBx+6c cohort, when compared to the TBx+12c cohort, demonstrated comparable diagnostic performance along with similar functional outcomes and lower complication rates. These results suggest the importance of further exploring the clinical implications of adopting a TBx+6c schema for PCa diagnosis in comparison to the widely used TBx+12c schema through a multicenter randomized controlled trial.
- 26 June 2024
- Published by Wiley in The Prostate
- Vol. 84 (13) , 1224-1233
Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes
Purpose: To compare the efficacy of a novel fusion template “reduced six‐core systemic template and multiparametric magnetic resonance imaging/transrectal ultrasound (mpMRI/TRUS) fusion targeted biopsy” (TBx+6c), with mpMRI/TRUS fusion‐targeted biopsy and 12‐core systematic biopsy template (TBx+12c) in the diagnosis of prostate cancer (PCa).Materials and Methods: This is an institutional review board approved single‐center observational study involving adult men undergoing fusion‐targeted biopsies for the diagnosis of PCa. Patients were sorted into cohorts of TBx+6c or TBx+12c based on the systematic biopsy template used. The study's main objective was to determine the cancer detection rate (CDR) for overall PCa and clinically significant PCa (csPCa) and the secondary objectives were to compare complication rates and functional outcome differences between the cohort.Results: A total of 204 patients met study's inclusion criteria. TBx+6c group had 120 patients, while TBx+12c cohort had 84 patients. The groups had similar baseline characteristics and overall CDR in the TBx+6c cohort was 71.7% versus 79.8%, compared to the TBx+12c (p = 0.18) whereas, the csPCa detection rate in the TBx+6c group was 50.8% versus 54.8% in the TBx+12c group (p = 0.5). TBx+6c cohort had lower overall complication rate of 3% versus 13%, (p = 0.01) and ≥ grade 2 complication rates (1 (1%) vs. 3(4%), p = 0.03) compared to the TBx+12c cohort. There were no differences in IIEF‐5 (p = 0.5) or IPSS (p = 0.1) scores at baseline and 2‐weeks and 6‐weeks post‐biopsy.Conclusion: TBx+6c cohort, when compared to the TBx+12c cohort, demonstrated comparable diagnostic performance along with similar functional outcomes and lower complication rates. These results suggest the importance of further exploring the clinical implications of adopting a TBx+6c schema for PCa diagnosis in comparison to the widely used TBx+12c schema through a multicenter randomized controlled trial.
- 19 July 2023
- Published by Wiley in The Prostate
- Vol. 83 (14) , 1373-1386
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score‐matched analysis
Background: Salvage cryotherapy (SCT) is widely used to treat prostate cancer (PCa) recurrence after radiotherapy (RT). We studied the intermediate oncological and functional outcomes of patients who underwent SCT following cryotherapy (CRYO‐SCT) recurrence and compare it to recurrence after brachytherapy (BT‐SCT).Methods: An IRB‐approved retrospective cohort study utilizing patient data from the Cryo On‐Line Data Registry and the Duke PCa database between 1992 and 2016. Biochemical recurrence (BCR) using Phoenix criteria was the primary endpoint assessed at 2‐ and 5‐years post‐SCT. Secondary endpoints assessed functional outcomes including urinary continence, erectile function, and recto‐urethral fistula. Association between treatment and biochemical progression‐free survival was assessed using inverse probability weighted (IPTW) Cox proportional hazards regression. The differences in the secondary functional outcomes were assessed by Pearson's χ2 test or Fisher's exact test, corrected for IPTW.Results: A total of 194 patients met inclusion criteria. The BCR rate for BT‐SCT and CRYO‐SCT was 23 (20.4%) and 17 (21%) at 2 years and 30 (26.5%) and 22 (27.2%) at 5 years according to Phoenix criteria. There was no statistical difference in 2 years (hazard ratio [HR] 0.9; 95% confidence interval [CI], 0.5–1.7, p = 0.7) or 5‐year BCR (HR: 0.86; 95% CI, 0.5‐1.5, p = 0.6) between the groups. The functional outcomes like urinary continence (p = 0.4), erectile function (p = 0.1), and recto‐urethral fistula (p = 0.3) were not statistically different.Conclusion: CRYO‐SCT appears to be well tolerated, with comparable oncological and functional outcomes to patients failing primary BT. The findings also demonstrated that SCT can render a significant number of patients biochemically free of disease after initial CRYO with minimal morbidity. SCT is a viable treatment option to salvage local PCa recurrence following either BT or cryoablation failure.
- 19 July 2023
- Published by Wiley in The Prostate
- Vol. 83 (14) , 1373-1386
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score‐matched analysis
Background: Salvage cryotherapy (SCT) is widely used to treat prostate cancer (PCa) recurrence after radiotherapy (RT). We studied the intermediate oncological and functional outcomes of patients who underwent SCT following cryotherapy (CRYO‐SCT) recurrence and compare it to recurrence after brachytherapy (BT‐SCT).Methods: An IRB‐approved retrospective cohort study utilizing patient data from the Cryo On‐Line Data Registry and the Duke PCa database between 1992 and 2016. Biochemical recurrence (BCR) using Phoenix criteria was the primary endpoint assessed at 2‐ and 5‐years post‐SCT. Secondary endpoints assessed functional outcomes including urinary continence, erectile function, and recto‐urethral fistula. Association between treatment and biochemical progression‐free survival was assessed using inverse probability weighted (IPTW) Cox proportional hazards regression. The differences in the secondary functional outcomes were assessed by Pearson's χ2 test or Fisher's exact test, corrected for IPTW.Results: A total of 194 patients met inclusion criteria. The BCR rate for BT‐SCT and CRYO‐SCT was 23 (20.4%) and 17 (21%) at 2 years and 30 (26.5%) and 22 (27.2%) at 5 years according to Phoenix criteria. There was no statistical difference in 2 years (hazard ratio [HR] 0.9; 95% confidence interval [CI], 0.5–1.7, p = 0.7) or 5‐year BCR (HR: 0.86; 95% CI, 0.5‐1.5, p = 0.6) between the groups. The functional outcomes like urinary continence (p = 0.4), erectile function (p = 0.1), and recto‐urethral fistula (p = 0.3) were not statistically different.Conclusion: CRYO‐SCT appears to be well tolerated, with comparable oncological and functional outcomes to patients failing primary BT. The findings also demonstrated that SCT can render a significant number of patients biochemically free of disease after initial CRYO with minimal morbidity. SCT is a viable treatment option to salvage local PCa recurrence following either BT or cryoablation failure.
- 2 April 2022
- Published by Elsevier in European Urology
- Vol. 40 (5) , 199.e9-199.e14
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database
- 2 April 2022
- Published by Elsevier in European Urology
- Vol. 40 (5) , 199.e9-199.e14
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database
- Open Access
- 1 January 2022
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 40 (3) , 631-639
Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
Michael ZD, et al. World J Mens Health. 2022 Aug;40:e60. https://doi.org/10.5534/wjmh.220068
- 1 January 2022
- Published by Korean Society for Sexual Medicine and Andrology in The World Journal of Men's Health
- Vol. 40 (3) , 631-639
Open AccessInitial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen
Michael ZD, et al. World J Mens Health. 2022 Aug;40:e60. https://doi.org/10.5534/wjmh.220068